You are here

Approvable Letter Issued for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension

ISELIN, N.J., Aug. 9 /PRNewswire-FirstCall/ -- Pharmos Corporation former marketing partner, Bausch & Lomb, has received from the U.S. Food and Drug Agency (FDA) an approvable letter for ZyLET, the NDA for which was filed by Bausch & Lomb last year. The first disclosure of this event was made by Bausch & Lomb in a Form 10Q filed on August 3, 2004, in which Bausch & Lomb also indicates it continues to target approval of ZyLET in the second half of 2004. Details of the approvable letter have not been publicly disclosed by Bausch & Lomb.

In 2001, Bausch & Lomb acquired the rights to the loteprednol etabonate ophthalmic business of Pharmos Corporation. Bausch & Lomb will pay Pharmos a milestone payment upon approval to market the product.

ZyLET is a loteprednol etabonate and tobramycin ophthalmic suspension. The combination therapy is aimed at treating patients with steroid-responsive inflammatory ocular conditions who have or are at risk of developing superficial bacterial ocular infections.

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status